View ValuationBICO Group 将来の成長Future 基準チェック /16BICO Group利益と収益がそれぞれ年間97.6%と7.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-2.6% 97.7%なると予測されています。主要情報97.6%収益成長率97.67%EPS成長率Life Sciences 収益成長20.2%収益成長率7.7%将来の株主資本利益率-2.64%アナリストカバレッジLow最終更新日12 May 2026今後の成長に関する最新情報Breakeven Date Change • Jul 09Forecast to breakeven in 2027The 3 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr10.0m in 2027. Average annual earnings growth of 84% is required to achieve expected profit on schedule.Breakeven Date Change • Mar 04Forecast breakeven date pushed back to 2027The 2 analysts covering BICO Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 28% per year to 2026. The company is expected to make a profit of kr79.8m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.Breakeven Date Change • Nov 15Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.Breakeven Date Change • Jun 11No longer forecast to breakevenThe analyst covering BICO Group no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr31.3m in 2024. New forecast suggests the company will make a loss of kr131.0m in 2025.Breakeven Date Change • Oct 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 112% is required to achieve expected profit on schedule.Breakeven Date Change • Jul 21Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 105% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesReported Earnings • May 02First quarter 2026 earnings released: kr1.86 loss per share (vs kr3.32 loss in 1Q 2025)First quarter 2026 results: kr1.86 loss per share (improved from kr3.32 loss in 1Q 2025). Revenue: kr329.9m (down 1.5% from 1Q 2025). Net loss: kr131.3m (loss narrowed 44% from 1Q 2025). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.お知らせ • Apr 01BICO Group AB (publ) Announces Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm Decline Re-Election as Members of the Board of DirectorsBICO Group AB (publ) announced that at the AGM to be held on May 7, 2026, Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm have declined re-election as members of the Board of Directors.お知らせ • Mar 24BICO Group AB (publ) to Report Fiscal Year 2026 Results on Feb 17, 2027BICO Group AB (publ) announced that they will report fiscal year 2026 results on Feb 17, 2027Reported Earnings • Feb 19Full year 2025 earnings released: kr22.38 loss per share (vs kr1.28 loss in FY 2024)Full year 2025 results: kr22.38 loss per share (further deteriorated from kr1.28 loss in FY 2024). Revenue: kr1.50b (down 23% from FY 2024). Net loss: kr1.58b (loss widened kr1.49b from FY 2024). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.New Risk • Feb 18New major risk - Revenue and earnings growthEarnings have declined by 43% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr78m net loss in 2 years).Reported Earnings • Nov 05Third quarter 2025 earnings released: kr15.68 loss per share (vs kr3.49 loss in 3Q 2024)Third quarter 2025 results: kr15.68 loss per share (further deteriorated from kr3.49 loss in 3Q 2024). Revenue: kr386.9m (down 22% from 3Q 2024). Net loss: kr1.11b (loss widened 349% from 3Q 2024). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.Board Change • Nov 03Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Susan Tousi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 13Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Susan Tousi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 11BICO Group AB (publ), Annual General Meeting, May 07, 2026BICO Group AB (publ), Annual General Meeting, May 07, 2026.Board Change • Sep 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Susan Tousi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 19Second quarter 2025 earnings released: kr2.55 loss per share (vs kr1.10 loss in 2Q 2024)Second quarter 2025 results: kr2.55 loss per share (further deteriorated from kr1.10 loss in 2Q 2024). Revenue: kr324.2m (down 39% from 2Q 2024). Net loss: kr179.8m (loss widened 131% from 2Q 2024). Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.New Risk • Jul 10New major risk - Revenue and earnings growthEarnings have declined by 42% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 42% per year over the past 5 years.Breakeven Date Change • Jul 09Forecast to breakeven in 2027The 3 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr10.0m in 2027. Average annual earnings growth of 84% is required to achieve expected profit on schedule.お知らせ • Jul 03Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO).Sartorius Lab Holding GmbH entered into an agreement to acquire MatTek Corporation from BICO Group AB (publ) (OM:BICO) for $80 million on April 4, 2025. The consideration is in cash and debt-free basis. The transaction includes the acquisition of Visikol Inc. During 2024, the business operations of Visikol were merged and operationally integrated into MatTek. For the period ending December 31, 2024, MatTek Corporation reported total revenue of $20 million. MatTek employs more than 80 people. The closing of the transaction is subject to customary regulatory approvals which are expected to be obtained during Q2 2025. Carnegie Investment Bank AB acted as financial advisor for BICO Group AB. Foley & Lardner LLP acted as legal advisor for BICO Group AB. PricewaterhouseCoopers Sweden acted as accountant for BICO Group AB. Led by Michael Bernhardt, Dean W. Sattler, Max Goodman, Alexander Rinne, and John Garces, Milbank LLP acted as legal advisor to Sartorius. Led by Matthias Zahn, Tobias Neukirchner, Kai Schmidt, Steven Wender, Sabrina Trümbach, Christoph Götz, Frank Breitenfeldt, Steve Ratmeyer, Kimberly Setz, and Susann Sturm, Rödl & Partner acted as financial advisor and accountant to Sartorius. Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO) on July 1, 2025.お知らせ • Jun 25BICO Group AB Announces Change in General CounselBICO Group AB announced the appointment of Lars Risberg as General Counsel. He will succeed Andréas Joersjö, who has decided to leave BICO to pursue his career outside the Group. Lars Risberg has 20+ years of working as a General Counsel (GC) and attorney at law whereof the last four years as General Counsel for Vitrolife Group. Prior to that Lars worked as Regional Lead Counsel Northwest Europe for Dekra and as attorney at law at Awa Patent and Setterwalls Business Law firm. Lars Risberg will be joining BICO on June 26 and Andreas Joersjö will remain at BICO until August 31 for handover to Lars Risberg. As General Counsel Lars Risberg will report to BICO’s President and CEO and be a member of the Executive Management.お知らせ • May 09BICO Group AB (publ) Announces Board ChangesBICO Group AB (publ) at the AGM held on May 8, 2025, the shareholders approved Johan Westman were elected new members of the Board of Directors. The members of the Board of Directors, Ulrika Dellby and Helena Skåntorp, had announced that they were not available for re-election.お知らせ • Apr 07BICO Group AB (publ) Announces Ulrika Dellby and Helena Skåntorp Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting to be held on May 8, 2025, Ulrika Dellby and Helena Skåntorp have declined re-election of the Board of Directors.Buy Or Sell Opportunity • Mar 27Now 21% undervaluedOver the last 90 days, the stock has risen 6.4% to €3.08. The fair value is estimated to be €3.90, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last 3 years. Earnings per share has declined by 69%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 38% in the next 2 years.Reported Earnings • Mar 25Full year 2024 earnings released: kr1.28 loss per share (vs kr11.16 loss in FY 2023)Full year 2024 results: kr1.28 loss per share (improved from kr11.16 loss in FY 2023). Revenue: kr1.95b (down 3.2% from FY 2023). Net loss: kr90.1m (loss narrowed 89% from FY 2023). Post-clinical trial products Launched (during full year): 7 Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.Breakeven Date Change • Mar 04Forecast breakeven date pushed back to 2027The 2 analysts covering BICO Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 28% per year to 2026. The company is expected to make a profit of kr79.8m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.Reported Earnings • Feb 19Full year 2024 earnings releasedFull year 2024 results: Net income: (up kr1.70b from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.New Risk • Feb 19New major risk - Revenue and earnings growthEarnings have declined by 75% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 75% per year over the past 5 years.お知らせ • Nov 29Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million.Lab14 GmbH agreed to acquire Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million on November 21, 2024. Following net debt and working capital adjustments, the equity value amounts to €26 million (SEK 294 million). Net proceeds, following transaction expenses, will be used to reduce long term debt. Nanoscribe revenue LTM September 2024 amounted to SEK 230 million (€19.826 million) and the adjusted EBITDA margin to 12 percent according to IFRS. The transaction is expected to close during the fourth quarter 2024. Bryan, Garnier & Co acted as financial advisor and Clemens Höhn, Matthias Rothkopf, Jan D. Bonhage, Christian Dankerl, Markus Ernst and Sonnhild Draack of Hengeler Mueller acted as legal advisor to BICO Group. Lab14 GmbH completed the acquisition of Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) on November 28, 2024.Reported Earnings • Nov 26Third quarter 2024 earnings released: kr3.49 loss per share (vs kr1.00 loss in 3Q 2023)Third quarter 2024 results: kr3.49 loss per share (further deteriorated from kr1.00 loss in 3Q 2023). Revenue: kr495.5m (down 21% from 3Q 2023). Net loss: kr246.2m (loss widened 249% from 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 32 percentage points per year, which is a significant difference in performance.Breakeven Date Change • Nov 15Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.お知らせ • Oct 18+ 3 more updatesBICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 final results on Mar 20, 2025お知らせ • Oct 09BICO Group AB (publ), Annual General Meeting, May 08, 2025BICO Group AB (publ), Annual General Meeting, May 08, 2025.Reported Earnings • Aug 21Second quarter 2024 earnings released: kr1.10 loss per share (vs kr12.73 loss in 2Q 2023)Second quarter 2024 results: kr1.10 loss per share (improved from kr12.73 loss in 2Q 2023). Revenue: kr534.0m (down 4.4% from 2Q 2023). Net loss: kr77.9m (loss narrowed 91% from 2Q 2023). Revenue is forecast to grow 9.9% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 22 percentage points per year, which is a significant difference in performance.お知らせ • Jul 10BICO Group AB Announces Management ChangesBICO Group AB announced the appointment of Andréas Joersjö as General Counsel. He will succeed Lotta Bus who has decided to leave BICO to pursue her career outside the Group. Andréas Joersjö will assume his new position by mid-October 2024 at the latest. Andréas Joersjö has 15+ years of experience working in an international business environment as General Counsel, lawyer, and advisor. Before joining BICO, Andréas has worked for Swedish law firms Delphi and Hammarskiöld & Co, in connection with which he has had several in-house assignments with large companies in various businesses, as well as PwC, and most recently as General Counsel for Hedin Group. For Hedin Group he established and headed the Group's Legal & Compliance team and was also a member of the Executive Management. Andréas Joersjö will report to BICO's President and CEO and be a member of the Executive Management. He will assume his position by mid-October 2024 at the latest.New Risk • Jun 11New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: kr1.6b Forecast net loss in 1 year: kr60m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (kr60m net loss next year).Breakeven Date Change • Jun 11No longer forecast to breakevenThe analyst covering BICO Group no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr31.3m in 2024. New forecast suggests the company will make a loss of kr131.0m in 2025.お知らせ • May 23BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of DirectorsBICO Group AB (publ) at its AGM held on May 20, 2024, approved the election of Alexandra Gatzemeyer as new member of the Board of Directors.Reported Earnings • May 07First quarter 2024 earnings released: kr0.40 loss per share (vs kr1.67 loss in 1Q 2023)First quarter 2024 results: kr0.40 loss per share (improved from kr1.67 loss in 1Q 2023). Revenue: kr510.3m (down 5.1% from 1Q 2023). Net loss: kr28.2m (loss narrowed 76% from 1Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 34 percentage points per year, which is a significant difference in performance.お知らせ • Apr 19BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024BICO Group AB (publ) announced the appointment of Anders Fogelberg as Chief Commercial Officer (CCO). Commercial excellence has been defined as one of the top strategic priorities for BICO and this position is pivotal in setting and driving the strategy towards that target, i.e., in scaling the BICO business, increasing the commercialization efforts of the portfolio and further explore opportunities for collaborations and partnerships. Anders Fogelberg has 20+ years' experience of working with marketing and sales & business development in global organizations. He has extensive experience from different leadership positions foremost as a Managing Director for the SKF Group in Malaysia and Indonesia respectively. Before joining BICO, Anders has worked in the Med Tech industry now latest as Chief Marketing Officer and Head of Sales for Profundus and before that as CEO for Bellman & Symfon. Anders Fogelberg will assume his new position on June 13, 2024. The CCO role is newly established, will be a member of the Executive Management and report to BICO's CEO and President. The CCO will be main responsible for the commercial activities within the BICO Group and ensure cooperation between subsidiaries and that long-term partnerships are built with relevant partners throughout the global life science industry.お知らせ • Apr 16BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting on May 20, 2024, Gerry Mackay and Erik Gatenholm have declined re-election of the Board of Directors.お知らせ • Mar 15BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 results on Feb 19, 2025お知らせ • Mar 06+ 1 more updateBICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024BICO Group AB (publ) announced that they will report Q3, 2024 results on Nov 13, 2024Reported Earnings • Feb 22Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022)Full year 2023 results: kr24.05 loss per share (further deteriorated from kr12.94 loss in FY 2022). Revenue: kr2.58b (up 4.5% from FY 2022). Net loss: kr1.70b (loss widened 104% from FY 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.New Risk • Feb 20New major risk - Revenue and earnings growthEarnings have declined by 87% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 87% per year over the past 5 years.お知らせ • Jan 25BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HRBICO Group AB (publ) announced the appointment of Catharina Nordlund as Global Head of HR. The role will further strengthen the Executive Management and be responsible for shaping and executing BICO's global HR strategy in order to build a people and high-performance culture. Catharina Nordlund has 25+ years' experience of Human Resources (HR), Learning & Development as well as Sales and Marketing in global organizations. She has held various positions within the medtech and the life science industries at companies such as Cochlear Bone Anchored Solutions, Mölnlycke Health Care and Pfizer, and now latest as VP Global HR for Surgical Science. Her vast experience covers functional responsibility for HR as well as line manager positions within sales from the life science industry. Catharina Nordlund will be part of the Executive Management and report to the CEO and President.Recent Insider Transactions • Nov 18Group Chief Financial Officer recently bought €75k worth of stockOn the 15th of November, Jacob Thordenberg bought around 18k shares on-market at roughly €4.30 per share. This transaction increased Jacob's direct individual holding by 19x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jacob's only on-market trade for the last 12 months.お知らせ • Nov 15+ 4 more updatesBICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Mar 15, 2024Reported Earnings • Aug 23Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022)Second quarter 2023 results: kr12.73 loss per share (down from kr0.68 profit in 2Q 2022). Revenue: kr568.8m (down 3.1% from 2Q 2022). Net loss: kr898.3m (down kr941.9m from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.お知らせ • Aug 22+ 1 more updateBICO Group AB (publ) Announces Chief Executive Officer ChangesBICO Group AB (publ) announced that Erik Gatenholm, after initiating discussions with the Board of Directors, has decided to step down as CEO of BICO Group. Maria Forss has been appointed as CEO. Maria Forss will assume office on November 27, 2023, or sooner. Maria Forss (born 1972) has extensive international experience from leading positions in both medtech and pharma companies, such as Vitrolife and AstraZeneca. The last years within Vitrolife Maria Forss has as the Senior Vice President led the Consumables Business Area and before that she was the Vice President of Business Development and Global Marketing. Maria Forss has successfully developed businesses through the whole value chain and in the whole product life cycle as well as acquisitions and integration of companies. In order to enable a seamless transition, Erik Gatenholm will remain in his current position until Maria Forss assumes as new President and CEO. To secure continuity Erik Gatenholm will, as major shareholder, also remain in his role as board member of BICO.お知らせ • Aug 04Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million on August 3, 2023. According to customary processes, the transaction needs to seek approval by the city of Berlin and that is expected to take up to 3 months to complete. The transaction is expected to be completed in Q4, 2023. White & Case LLP acted as legal advisor and JLL acted as broker to BICO.お知らせ • May 10BICO Group AB (publ) Elects Gerry Mackay to Its Board of DirectorsBICO Group AB (publ) at its Annual General Meeting held on 9 May 2023, elected Gerry Mackay to Its Board of Directors.Reported Earnings • May 08First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022)First quarter 2023 results: kr1.67 loss per share (further deteriorated from kr0.68 loss in 1Q 2022). Revenue: kr537.6m (up 3.6% from 1Q 2022). Net loss: kr117.7m (loss widened 170% from 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.お知らせ • May 05BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Feb 20, 2024Reported Earnings • Feb 22Full year 2022 earnings released: kr13.00 loss per share (vs kr3.97 loss in FY 2021)Full year 2022 results: kr13.00 loss per share (further deteriorated from kr3.97 loss in FY 2021). Revenue: kr2.53b (up 84% from FY 2021). Net loss: kr832.9m (loss widened 266% from FY 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.Recent Insider Transactions • Jan 14Independent Chairman of the Board recently sold €747k worth of stockOn the 10th of January, Carsten Browall sold around 80k shares on-market at roughly €9.33 per share. This transaction amounted to 71% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Carsten has been a net seller over the last 12 months, reducing personal holdings by €654k.お知らせ • Jan 06BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023BICO Group AB announced the appointment of Marius Balger as Chief Operating Officer, as BICO continues to accelerate its growth journey across geographies and business strategies. Mr.Balger will be part of the Executive Management team and report directly to President & CEO Erik Gatenholm. As COO, Mr. Balger will take office 1 March 2023 and lead the strategic development of BICO’s operational efficiency and cost control. Mr. Balger brings nearly 20 years of experience in the global life science industry, most recently serving as Senior Vice President, Commercial Operations at Tecan AG, a public life science company headquartered in Zurich, where he has worked since 2017. Before Tecan AG, Mr. Balger had a long and esteemed career as CEO, successfully growing a global Contract Development and Manufacturing Organization for life science and in-vitro diagnostics laboratory instrumentation. In line with BICO's previously communicated strategy with a focus on cost control, operational efficiency, and decentralized organizational structure the Executive Management of BICO Group will, as of January 5, 2023, consist of the following people: President and CEO Erik Gatenholm; CTO Hector Martinez; CFO Jacob Thordenberg and SVP & General Counsel & HR Lotta Bus. As of 1 March 2023, both COO Marius Balger and Head of Corporate Development & M&A Artur Aira are included in the Executive Management team.お知らせ • Jan 03BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFOBICO Group AB announced the appointment of Jacob Thordenberg as Group CFO. Thordenberg will begin his employment in his new position as Group CFO, on January 2, 2023, and will be part of the company's executive management team. Jacob Thordenberg has a Master of Science in Corporate and Financial Management, and has more than ten years' experience from mergers and acquisitions from Deloitte, Telia and BICO Group AB. Most recently he comes from a role as Head of M&A at BICO, where he has been since December 2021. Thordenberg succeeds Mikael Engblom, who has been interim Group CFO since May 2022. Engblom will continue to advise the company on strategic projects.お知らせ • Nov 22BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023BICO Group AB (publ) announced that they will report Q1, 2023 results on May 04, 2023Buying Opportunity • Nov 16Now 28% undervaluedOver the last 90 days, the stock is up 70%. The fair value is estimated to be €9.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 59% in 2 years. Earnings is forecast to grow by 881% in the next 2 years.Reported Earnings • Nov 10Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr623.2m (up 79% from 3Q 2021). Net income: kr66.4m (up kr170.6m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • Nov 10BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023BICO Group AB (publ) announced that they will report Q2, 2023 results on Jul 20, 2023お知らせ • Oct 29+ 1 more updateBICO Group Announces Appointment of Nomination Committee 2023BICO Group´s major owners have appointed a Nomination Committee. The Annual General Meeting of BICO Group AB will be held on May 9, 2023. In preparation for the 2023 Annual General Meeting the members of the Nomination Committee have been appointed based on the ownership structure as per 30th of September 2022 and consists of: Mats Engström, nominated by Erik Gatenholm. Claes Dinkelspiel, nominated by Héctor Martínez. Malin Björkmo, nominated by Handelsbanken Fonder. Jannis Kitsakis, nominated by Fourth Swedish National Pension Fund. Carsten Browall, Chairman of the Board of BICO Group AB.Breakeven Date Change • Oct 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 112% is required to achieve expected profit on schedule.Reported Earnings • Aug 24Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr612.4m (up 88% from 2Q 2021). Net income: kr43.6m (up kr93.9m from 2Q 2021). Profit margin: 7.1% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 18%, compared to a 13% growth forecast for the Life Sciences industry in Germany.Breakeven Date Change • Jul 21Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 105% is required to achieve expected profit on schedule.Buying Opportunity • Jun 14Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 36%. The fair value is estimated to be €11.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 91% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • May 19First quarter 2022 earnings released: kr0.68 loss per share (vs kr0.90 loss in 1Q 2021)First quarter 2022 results: kr0.68 loss per share (up from kr0.90 loss in 1Q 2021). Revenue: kr537.4m (up 250% from 1Q 2021). Net loss: kr43.6m (loss narrowed 8.2% from 1Q 2021). Over the next year, revenue is forecast to grow 41%, compared to a 13% growth forecast for the industry in Germany.お知らせ • May 18+ 1 more updateBICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023BICO Group AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2023お知らせ • May 12BICO Group Adds Åsa Hillsten as SVP and Head of IRÅsa Hillsten has been appointed SVP and Head of IR at BICO and will be a member of the company's executive management This newly created position constitutes a step in BICO's continued efforts to increase the service level to the market, improve the clarity of its communication and clarify its business model for the investor market. Åsa Hillsten has more than fifteen years of solid experience in international strategic communication and IR issues at the executive management level at growth companies in several sectors. Former positions include Head of IR and communication roles at Catena Media (mid-cap) and Collector Bank (large cap), where she was also Head of PR. Hillsten will assume her position on August 8, 2022, but she will assist the company in an advisory capacity starting in May.お知らせ • May 08BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million on May 6, 2022. As a part of consideration the shareholders of Allegro will receive $5 million as Earnout Payment contingent on Allegro 3D's financial performance in the coming two years. BICO Group AB (publ) (OM : BICO) completed the acquisition of Allegro 3D on May 6, 2022.お知らせ • May 02BICO (publ) Appoints Mikael Engblom as Interim CFOMikael Engblom will take the position as interim CFO for BICO (publ) from 29 April 2022 until a new permanent CFO is in place. Engblom will be part of Group management during this period. Engblom most recently came from the role of CFO at Vitrolife. Prior to that, he worked as a controller at Vitrolife and Volvo Cars.Buying Opportunity • Apr 28Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 44%. The fair value is estimated to be €11.99, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 67% in a year. Earnings is forecast to grow by 83% in the next year.Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. No highly experienced directors. Independent Director Bengt Sjoholm is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 27+ 1 more updateBICO Group AB (Publ) Announces Board AppointmentsBICO Group AB (publ) at its annual general meeting held on April 26, 2022 elected Rolf Classon and Ulrika Dellby as new members of the Board of Directors.Recent Insider Transactions • Mar 04Co-Founder recently bought €94k worth of stockOn the 2nd of March, Erik Gatenholm bought around 6k shares on-market at roughly €15.89 per share. In the last 3 months, they made an even bigger purchase worth €1.9m. Despite this recent buy, Erik has been a net seller over the last 12 months, reducing personal holdings by €15m.Reported Earnings • Feb 24Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr3.97 loss per share (down from kr0.82 loss in FY 2020). Revenue: kr1.43b (up 283% from FY 2020). Net loss: kr227.6m (loss widened kr191.5m from FY 2020). Post-clinical trial products Launched (during full year): 3 Revenue exceeded analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 66%, compared to a 25% growth forecast for the pharmaceuticals industry in Germany.お知らせ • Feb 24BICO Reaches Beneficial and Sustainable Solution with OrganovoBICO have reached a settlement with Organovo in which BICO agreed to resolve all aspects of the disputes between the parties. Organovo and BICO were engaged in several legal disputes regarding Organovo's patents. Under the new agreement, all civil actions regarding potential infringements and IPRs concerning validity of Organovo's patents are dismissed and/or terminated. Both BICO and Organovo have released each other from all previous claims, demands, liabilities and costs in favor of finding a beneficial and sustainable solution created through this patent license agreement. The patent license agreement with Organovo provide BICO with possibilities to access Organovo's bioprinting technologies, which will further empower BICO to continue to advance and expand BICO's product portfolio. BICO offering will become even stronger by accessing these technologies and BICO, through group company CELLINK, will have the freedom to operate globally with the strongest and most extensive bioprinting portfolio on the market. The total annual revenue covered by the license agreement is expected to, as previously communicated via release on January 11, 2022, amount to approximately 1-2% of the Group's estimated revenues in 2022 and therefore is deemed as non-material for the Group.お知らせ • Feb 03DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022DISPENDIX, a BICO company, announces that the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022. Driven by several years of growth of the I.DOT non-contact Dispenser, DISPENDIX has invested in strategic R&D and industry partnerships to deliver two disruptive platforms that will come together to provide scientists with more holistic workflow solutions for genomics and drug discovery research. The I.DOT HT builds on the core technology of the I.DOT, expanding the source well layout to a 384 format to support the management of compound libraries at large pharmaceutical and smaller biotechnology companies. The I.DOT HT provides the same degree of precision and process safety that users have come to expect from the DISPENDIX family of products, while expanding the applicability of the I.DOT; now users can seal and store source plates that contain compound libraries for assay development, optimization, and screening. DISPENDIX has also announced the introduction of the L.DROP Liquid Handler with the goal of commoditizing laboratory automation. The L.DROP couples sensor technology and a web-based architecture to provide a more dynamic instrument that is capable of scaling protocols across instruments and even laboratories without tedious optimization. Features like automated deck calibration, web-based protocol fitting, and closed-loop pipetting promise to revolutionize the way that researchers and automation engineers leverage liquid handling technologies. This launch is the latest in DISPENDIX's mission to deliver simple and elegant solutions for the liquid handling industry. These products will be on display and demoed at the upcoming SLAS (Society for Laboratory Automation and Screening) in Boston from February 7-9, 2022 at booth 2727.お知らせ • Jan 12BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against CellinkDue to recently filed counterclaims in patent lawsuit by Organovo, Inc., (Organovo) to the Federal Court in Delaware, BICO Group AB (BICO) released the following statement to explain the background and context. BICO, CELLINK and all its group companies respect valid intellectual property and believe that Organovo's patent claims at issue are invalid, not infringed, or both. CELLINK filed a complaint for a declaratory judgment in June 2021 to the U.S. District Court in Delaware about non-infringement of certain of Organovo's patents in order to strengthen its market position and freedom to operate. In July, 2021, Organovo, filed a patent infringement action against CELLINK in the U.S. District Court in the Western District of Texas, asserting that a single CELLINK product family infringes four U.S. patents. Organovo'sTexas Court Action was later, in December 2021, transferred to the Delaware Court and both cases will from now on be tried by the Delaware court. The so-called counterclaims filed by Organovo in January 2022 refers to the transferred claims from the Texas Court.Recent Insider Transactions • Dec 18Co-Founder recently bought €1.9m worth of stockOn the 16th of December, Erik Gatenholm bought around 74k shares on-market at roughly €26.32 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Erik has been a net seller over the last 12 months, reducing personal holdings by €15m.お知らせ • Dec 17BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc on December 16, 2021. Approximately 63 percent of the purchase price will be paid in cash, 21 precent by issuance of the Considerations Shares, and approximately 16 percent will be paid through an earnout component (shares and cash) over the coming three years. At closing 1.2 million Consideration shares will be issued to the sellers. Biosero will remain under current entity and management post-transaction. Biosero has an enterprise value of $165 million. BICO’s Board of Directors will resolve to issue the Consideration Shares in accordance with the authorization from the Extraordinary General Meeting held on November 17, 2021. The Acquisition’s completion and the transfer of Biosero’s shares will take place as soon as reasonably possible after signing, provided that all conditions for completion are met. In addition, and as a closing pre-condition, the completion of the Acquisition is dependent on approval by the relevant competition authorities. Biosero will be consolidated in BICO's financial statements and in the financial reporting from Q1, 2022. Foley & Lardner acts as legal advisors to BICO in connection with the Acquisition, PwC advises on financial and tax due diligence.Reported Earnings • Nov 12Third quarter 2021 earnings releasedThe company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr347.3m (up 457% from 3Q 2020). Net loss: kr104.2m (loss widened kr90.0m from 3Q 2020).Recent Insider Transactions • Sep 01Insider recently sold €1.1m worth of stockOn the 23rd of August, Jonas Schondube sold around 20k shares on-market at roughly €53.24 per share. In the last 3 months, there was an even bigger sale from another insider worth €17m. Insiders have been net sellers, collectively disposing of €50m more than they bought in the last 12 months.お知らせ • Aug 28BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million on August 27, 2021. The consideration settled on a cash and debt-free basis of approximately $15 million, provided that the working capital upon completion of the transaction corresponds to the normalized working capital. The sellers may also receive a maximum additional earn out of $3 million in cash based on milestones over a three-year period. Advanced BioMatrix obtained approximately USD 3 million, with an adjusted EBITDA margin of around 50% in their latest fiscal year. Post transaction, Advanced BioMatrix will remain under current legal entity and management as a subsidiary of BICO Group Bioprinting and become part of the Bioprinting business area. Advanced BioMatrix will be integrated in the financial reporting as of August 2021. BICO Group AB (publ) (OM:BICO) completed the acquisition of all outstanding shares in Advanced BioMatrix, Inc. on August 27, 2021.Recent Insider Transactions • Aug 25CEO & Director recently sold €17m worth of stockOn the 18th of August, Erik Gatenholm sold around 280k shares on-market at roughly €59.24 per share. This was the largest sale by an insider in the last 3 months. This was Erik's only on-market trade for the last 12 months.Reported Earnings • Aug 21Second quarter 2021 earnings released: kr0.89 loss per share (vs kr0.58 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr328.4m (up kr275.8m from 2Q 2020). Net loss: kr50.3m (loss widened 99% from 2Q 2020).お知らせ • Jul 03CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical ProceduresCELLINK has been granted a patent for a unique set of robotic systems for transcutaneous delivery of substances, such as cosmetic or surgical fillers, into patients. This is CELLINK’s first granted patent in the field of personalized and automated aesthetic medical procedures - combining the strengths of 3D bioprinting, biomaterials, robotics, automation, and artificial intelligence to optimally administer substances, such as dermal fillers, into subcutaneous regions to improve aesthetical outcomes in patients. This is one technological example of the power of Bioconvergence. This patent protection applies to the Swedish market. The company is also expanding patent protection in the USA and other important markets. The patent protection (SE 543714) from the Swedish Patent and Registration Office shows novelty, inventive step, and industrial applicability. Aesthetic plastic surgery is a field where CELLINK sees great opportunities and potential to disrupt by personalizing, digitizing, and automating the processes. The patented invention covers the use of a person’s 3D face scan as a digital input to compare to the person’s desired bodily features. Based on the results from the artificial intelligence powered algorithm, determine an optimal substance dispensing plan that can be executed autonomously and precisely by a robotic arm in the required facial regions with the adequate type of dermal filler and amounts. The personalized and automated approach may provide a faster and more accurate substance dispensing plan than a human counterpart would be able to do, may reduce treatment times and probability of complications associated with dispensing the substance, while simultaneously achieving superior results compared to the human counterpart.お知らせ • Jul 01Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Discover Echo Inc. for $110 million on June 26, 2021. The consideration is on a cash- and debt-free basis, and under the assumption that the working capital at closing equals the normalized working capital. Pursuant to the agreement, Cellink AB (publ) shall pay approximately 11% of consideration through issuance of shares of series B while remaining payable in cash. Discover Echo Inc. will remain under current entity and management post-transaction. Cellink AB (publ) Board of Directors will resolve on an issue in kind of the Consideration Shares in accordance with the authorization from the Annual General Meeting held on April 26, 2021. Post satisfaction of all conditions for the transaction, completion will take place as soon as possible. Foley & Lardner acted as legal advisors to CELLINK in connection with the transaction while Duff & Phelps advises on financial and tax due diligence. Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc. on June 30, 2021. Total purchase price of $110 million of which approximately $12.5 million was paid in 0.26 million newly issued shares of series B in CELLINK and the reminder in cash.お知らせ • Jun 01Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for approximately €50 million on May 19, 2021. The consideration is on cash- and debt-free basis. Consideration consists of approximately €34 million as fixed purchase price and approximately €16 million in earn-outs. Approximately 35% of the fixed purchase price of €34 million will be paid in newly issued shares of series B in CELLINK and the remaining portion will be paid cash. The earn-out is paid based on target fulfillment of financial targets for the fiscal years 2021–2023. Hans-Jörg Ziegenhain, Elisabeth Kreuzer, Markus Ernst, Dirk Uwer, Hendrik Bockenheimer, Jakub Lorys, Susanne Koch and Patrick Wilkening of Hengeler Mueller Partnerschaft von Rechtsanwälten mbB acted as legal advisors, Duff & Phelps GmbH acted as financial and tax due diligence provider and Zacco Gmbh acted as intellectual property due diligence provider to Cellink. Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million on May 31, 2021. The purchase price for all shares amounted to approximately €36.9 million based on net cash/debt and of which approximately €12.2 million was paid in 301,332 newly issued shares of series B in CELLINK and the reminder in cash.お知らせ • May 21Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million on May 19, 2021. Consideration consists of approximately €16 million in earn-outs. The earn-out is paid based on target fulfillment of financial targets for the fiscal years 2021–2023. Approximately thirty-five percent of the fixed purchase price of €34 million will be paid in newly issued shares of series B in CELLINK (the “Consideration Shares”) and the remaining part which consists of an earn-out will be paid cash. Hengeler Mueller Partnerschaft von Rechtsanwälten mbB acted as legal advisor, Duff & Phelps GmbH acted as financial and tax due diligence provider and Zacco Gmbh acted as intellectual property due diligence provider to Cellink.業績と収益の成長予測BST:49Z - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20281,839-4985126312/31/20271,689-112-1144312/31/20261,566-207-97-5633/31/20261,492-1,4771539N/A12/31/20251,497-1,5804368N/A9/30/20251,561-1,270159199N/A6/30/20251,543-424216275N/A3/31/20251,642-323176252N/A12/31/20241,727-10773158N/A9/30/20241,609-80348139N/A6/30/20241,828-583-3598N/A3/31/20241,941-729-98101N/A12/31/20232,010-788-113178N/A9/30/20232,213-497-435-53N/A6/30/20232,256-390-527-72N/A3/31/20232,297-117-643-140N/A12/31/20222,327-85-799-269N/A9/30/20222,27841-817-313N/A6/30/20221,995-130-872-457N/A3/31/20221,743-224-816-462N/A12/31/20211,378-228-676-409N/A9/30/2021993-188-529-321N/A6/30/2021744-96-328-150N/A3/31/2021460-50-156-34N/A12/31/2020369-36-160-59N/A8/31/2020236-62-154-72N/A5/31/2020213-49-146-70N/A2/29/2020197-24N/A-53N/A11/30/2019173-5N/A-31N/A8/31/20191351N/A-16N/A5/31/20191183N/A-16N/A2/28/2019974N/A-2N/A11/30/2018762N/A-12N/A8/31/2018611N/A-12N/A5/31/2018451N/A-6N/A2/28/201834-2N/A-7N/A11/30/201727-2N/A-8N/A8/31/201720-1N/A-1N/A8/31/20166-1N/A-2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 49Z今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 49Z今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 49Z今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 49Zの収益 ( 7.7% ) German市場 ( 6.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 49Zの収益 ( 7.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 49Z 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 06:55終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋BICO Group AB (publ) 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Kristofer Liljeberg-SvenssonDNB CarnegieLudvig LundgrenNordea MarketsFilip EinarssonRedeye
Breakeven Date Change • Jul 09Forecast to breakeven in 2027The 3 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr10.0m in 2027. Average annual earnings growth of 84% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 04Forecast breakeven date pushed back to 2027The 2 analysts covering BICO Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 28% per year to 2026. The company is expected to make a profit of kr79.8m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
Breakeven Date Change • Nov 15Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.
Breakeven Date Change • Jun 11No longer forecast to breakevenThe analyst covering BICO Group no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr31.3m in 2024. New forecast suggests the company will make a loss of kr131.0m in 2025.
Breakeven Date Change • Oct 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 112% is required to achieve expected profit on schedule.
Breakeven Date Change • Jul 21Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 105% is required to achieve expected profit on schedule.
Reported Earnings • May 02First quarter 2026 earnings released: kr1.86 loss per share (vs kr3.32 loss in 1Q 2025)First quarter 2026 results: kr1.86 loss per share (improved from kr3.32 loss in 1Q 2025). Revenue: kr329.9m (down 1.5% from 1Q 2025). Net loss: kr131.3m (loss narrowed 44% from 1Q 2025). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 01BICO Group AB (publ) Announces Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm Decline Re-Election as Members of the Board of DirectorsBICO Group AB (publ) announced that at the AGM to be held on May 7, 2026, Susan Tousi, Alexandra Gatzemeyer and Bengt Sjöholm have declined re-election as members of the Board of Directors.
お知らせ • Mar 24BICO Group AB (publ) to Report Fiscal Year 2026 Results on Feb 17, 2027BICO Group AB (publ) announced that they will report fiscal year 2026 results on Feb 17, 2027
Reported Earnings • Feb 19Full year 2025 earnings released: kr22.38 loss per share (vs kr1.28 loss in FY 2024)Full year 2025 results: kr22.38 loss per share (further deteriorated from kr1.28 loss in FY 2024). Revenue: kr1.50b (down 23% from FY 2024). Net loss: kr1.58b (loss widened kr1.49b from FY 2024). Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.4% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 47% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.
New Risk • Feb 18New major risk - Revenue and earnings growthEarnings have declined by 43% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr78m net loss in 2 years).
Reported Earnings • Nov 05Third quarter 2025 earnings released: kr15.68 loss per share (vs kr3.49 loss in 3Q 2024)Third quarter 2025 results: kr15.68 loss per share (further deteriorated from kr3.49 loss in 3Q 2024). Revenue: kr386.9m (down 22% from 3Q 2024). Net loss: kr1.11b (loss widened 349% from 3Q 2024). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
Board Change • Nov 03Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Susan Tousi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 13Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Susan Tousi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 11BICO Group AB (publ), Annual General Meeting, May 07, 2026BICO Group AB (publ), Annual General Meeting, May 07, 2026.
Board Change • Sep 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Susan Tousi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 19Second quarter 2025 earnings released: kr2.55 loss per share (vs kr1.10 loss in 2Q 2024)Second quarter 2025 results: kr2.55 loss per share (further deteriorated from kr1.10 loss in 2Q 2024). Revenue: kr324.2m (down 39% from 2Q 2024). Net loss: kr179.8m (loss widened 131% from 2Q 2024). Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
New Risk • Jul 10New major risk - Revenue and earnings growthEarnings have declined by 42% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 42% per year over the past 5 years.
Breakeven Date Change • Jul 09Forecast to breakeven in 2027The 3 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr10.0m in 2027. Average annual earnings growth of 84% is required to achieve expected profit on schedule.
お知らせ • Jul 03Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO).Sartorius Lab Holding GmbH entered into an agreement to acquire MatTek Corporation from BICO Group AB (publ) (OM:BICO) for $80 million on April 4, 2025. The consideration is in cash and debt-free basis. The transaction includes the acquisition of Visikol Inc. During 2024, the business operations of Visikol were merged and operationally integrated into MatTek. For the period ending December 31, 2024, MatTek Corporation reported total revenue of $20 million. MatTek employs more than 80 people. The closing of the transaction is subject to customary regulatory approvals which are expected to be obtained during Q2 2025. Carnegie Investment Bank AB acted as financial advisor for BICO Group AB. Foley & Lardner LLP acted as legal advisor for BICO Group AB. PricewaterhouseCoopers Sweden acted as accountant for BICO Group AB. Led by Michael Bernhardt, Dean W. Sattler, Max Goodman, Alexander Rinne, and John Garces, Milbank LLP acted as legal advisor to Sartorius. Led by Matthias Zahn, Tobias Neukirchner, Kai Schmidt, Steven Wender, Sabrina Trümbach, Christoph Götz, Frank Breitenfeldt, Steve Ratmeyer, Kimberly Setz, and Susann Sturm, Rödl & Partner acted as financial advisor and accountant to Sartorius. Sartorius Lab Holding GmbH completed the acquisition of MatTek Corporation from BICO Group AB (publ) (OM:BICO) on July 1, 2025.
お知らせ • Jun 25BICO Group AB Announces Change in General CounselBICO Group AB announced the appointment of Lars Risberg as General Counsel. He will succeed Andréas Joersjö, who has decided to leave BICO to pursue his career outside the Group. Lars Risberg has 20+ years of working as a General Counsel (GC) and attorney at law whereof the last four years as General Counsel for Vitrolife Group. Prior to that Lars worked as Regional Lead Counsel Northwest Europe for Dekra and as attorney at law at Awa Patent and Setterwalls Business Law firm. Lars Risberg will be joining BICO on June 26 and Andreas Joersjö will remain at BICO until August 31 for handover to Lars Risberg. As General Counsel Lars Risberg will report to BICO’s President and CEO and be a member of the Executive Management.
お知らせ • May 09BICO Group AB (publ) Announces Board ChangesBICO Group AB (publ) at the AGM held on May 8, 2025, the shareholders approved Johan Westman were elected new members of the Board of Directors. The members of the Board of Directors, Ulrika Dellby and Helena Skåntorp, had announced that they were not available for re-election.
お知らせ • Apr 07BICO Group AB (publ) Announces Ulrika Dellby and Helena Skåntorp Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting to be held on May 8, 2025, Ulrika Dellby and Helena Skåntorp have declined re-election of the Board of Directors.
Buy Or Sell Opportunity • Mar 27Now 21% undervaluedOver the last 90 days, the stock has risen 6.4% to €3.08. The fair value is estimated to be €3.90, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last 3 years. Earnings per share has declined by 69%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to grow by 38% in the next 2 years.
Reported Earnings • Mar 25Full year 2024 earnings released: kr1.28 loss per share (vs kr11.16 loss in FY 2023)Full year 2024 results: kr1.28 loss per share (improved from kr11.16 loss in FY 2023). Revenue: kr1.95b (down 3.2% from FY 2023). Net loss: kr90.1m (loss narrowed 89% from FY 2023). Post-clinical trial products Launched (during full year): 7 Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 28 percentage points per year, which is a significant difference in performance.
Breakeven Date Change • Mar 04Forecast breakeven date pushed back to 2027The 2 analysts covering BICO Group previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 28% per year to 2026. The company is expected to make a profit of kr79.8m in 2027. Average annual earnings growth of 51% is required to achieve expected profit on schedule.
Reported Earnings • Feb 19Full year 2024 earnings releasedFull year 2024 results: Net income: (up kr1.70b from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.
New Risk • Feb 19New major risk - Revenue and earnings growthEarnings have declined by 75% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 75% per year over the past 5 years.
お知らせ • Nov 29Lab14 GmbH acquired Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million.Lab14 GmbH agreed to acquire Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) for €26 million on November 21, 2024. Following net debt and working capital adjustments, the equity value amounts to €26 million (SEK 294 million). Net proceeds, following transaction expenses, will be used to reduce long term debt. Nanoscribe revenue LTM September 2024 amounted to SEK 230 million (€19.826 million) and the adjusted EBITDA margin to 12 percent according to IFRS. The transaction is expected to close during the fourth quarter 2024. Bryan, Garnier & Co acted as financial advisor and Clemens Höhn, Matthias Rothkopf, Jan D. Bonhage, Christian Dankerl, Markus Ernst and Sonnhild Draack of Hengeler Mueller acted as legal advisor to BICO Group. Lab14 GmbH completed the acquisition of Nanoscribe GmbH from BICO Group AB (publ) (OM:BICO) on November 28, 2024.
Reported Earnings • Nov 26Third quarter 2024 earnings released: kr3.49 loss per share (vs kr1.00 loss in 3Q 2023)Third quarter 2024 results: kr3.49 loss per share (further deteriorated from kr1.00 loss in 3Q 2023). Revenue: kr495.5m (down 21% from 3Q 2023). Net loss: kr246.2m (loss widened 249% from 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 32 percentage points per year, which is a significant difference in performance.
Breakeven Date Change • Nov 15Forecast to breakeven in 2026The 2 analysts covering BICO Group expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 87% per year to 2025. The company is expected to make a profit of kr100.4m in 2026. Average annual earnings growth of 130% is required to achieve expected profit on schedule.
お知らせ • Oct 18+ 3 more updatesBICO Group AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 final results on Mar 20, 2025
お知らせ • Oct 09BICO Group AB (publ), Annual General Meeting, May 08, 2025BICO Group AB (publ), Annual General Meeting, May 08, 2025.
Reported Earnings • Aug 21Second quarter 2024 earnings released: kr1.10 loss per share (vs kr12.73 loss in 2Q 2023)Second quarter 2024 results: kr1.10 loss per share (improved from kr12.73 loss in 2Q 2023). Revenue: kr534.0m (down 4.4% from 2Q 2023). Net loss: kr77.9m (loss narrowed 91% from 2Q 2023). Revenue is forecast to grow 9.9% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 22 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 10BICO Group AB Announces Management ChangesBICO Group AB announced the appointment of Andréas Joersjö as General Counsel. He will succeed Lotta Bus who has decided to leave BICO to pursue her career outside the Group. Andréas Joersjö will assume his new position by mid-October 2024 at the latest. Andréas Joersjö has 15+ years of experience working in an international business environment as General Counsel, lawyer, and advisor. Before joining BICO, Andréas has worked for Swedish law firms Delphi and Hammarskiöld & Co, in connection with which he has had several in-house assignments with large companies in various businesses, as well as PwC, and most recently as General Counsel for Hedin Group. For Hedin Group he established and headed the Group's Legal & Compliance team and was also a member of the Executive Management. Andréas Joersjö will report to BICO's President and CEO and be a member of the Executive Management. He will assume his position by mid-October 2024 at the latest.
New Risk • Jun 11New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: kr1.6b Forecast net loss in 1 year: kr60m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Currently unprofitable and not forecast to become profitable next year (kr60m net loss next year).
Breakeven Date Change • Jun 11No longer forecast to breakevenThe analyst covering BICO Group no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr31.3m in 2024. New forecast suggests the company will make a loss of kr131.0m in 2025.
お知らせ • May 23BICO Group AB (publ) Elects Alexandra Gatzemeyer as Member of the Board of DirectorsBICO Group AB (publ) at its AGM held on May 20, 2024, approved the election of Alexandra Gatzemeyer as new member of the Board of Directors.
Reported Earnings • May 07First quarter 2024 earnings released: kr0.40 loss per share (vs kr1.67 loss in 1Q 2023)First quarter 2024 results: kr0.40 loss per share (improved from kr1.67 loss in 1Q 2023). Revenue: kr510.3m (down 5.1% from 1Q 2023). Net loss: kr28.2m (loss narrowed 76% from 1Q 2023). Revenue is forecast to grow 10% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 34 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 19BICO Group AB (publ) Announces the Appointment of Anders Fogelberg as Chief Commercial Officer, Effective June 13, 2024BICO Group AB (publ) announced the appointment of Anders Fogelberg as Chief Commercial Officer (CCO). Commercial excellence has been defined as one of the top strategic priorities for BICO and this position is pivotal in setting and driving the strategy towards that target, i.e., in scaling the BICO business, increasing the commercialization efforts of the portfolio and further explore opportunities for collaborations and partnerships. Anders Fogelberg has 20+ years' experience of working with marketing and sales & business development in global organizations. He has extensive experience from different leadership positions foremost as a Managing Director for the SKF Group in Malaysia and Indonesia respectively. Before joining BICO, Anders has worked in the Med Tech industry now latest as Chief Marketing Officer and Head of Sales for Profundus and before that as CEO for Bellman & Symfon. Anders Fogelberg will assume his new position on June 13, 2024. The CCO role is newly established, will be a member of the Executive Management and report to BICO's CEO and President. The CCO will be main responsible for the commercial activities within the BICO Group and ensure cooperation between subsidiaries and that long-term partnerships are built with relevant partners throughout the global life science industry.
お知らせ • Apr 16BICO Group AB (publ) Announces Gerry Mackay and Erik Gatenholm Decline Re-Election of the Board of DirectorsBICO Group AB (publ) at the Annual General Meeting on May 20, 2024, Gerry Mackay and Erik Gatenholm have declined re-election of the Board of Directors.
お知らせ • Mar 15BICO Group AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025BICO Group AB (publ) announced that they will report fiscal year 2024 results on Feb 19, 2025
お知らせ • Mar 06+ 1 more updateBICO Group AB (publ) to Report Q3, 2024 Results on Nov 13, 2024BICO Group AB (publ) announced that they will report Q3, 2024 results on Nov 13, 2024
Reported Earnings • Feb 22Full year 2023 earnings released: kr24.05 loss per share (vs kr12.94 loss in FY 2022)Full year 2023 results: kr24.05 loss per share (further deteriorated from kr12.94 loss in FY 2022). Revenue: kr2.58b (up 4.5% from FY 2022). Net loss: kr1.70b (loss widened 104% from FY 2022). Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance.
New Risk • Feb 20New major risk - Revenue and earnings growthEarnings have declined by 87% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 87% per year over the past 5 years.
お知らせ • Jan 25BICO Group AB (publ) Appoints Catharina Nordlund as Global Head of HRBICO Group AB (publ) announced the appointment of Catharina Nordlund as Global Head of HR. The role will further strengthen the Executive Management and be responsible for shaping and executing BICO's global HR strategy in order to build a people and high-performance culture. Catharina Nordlund has 25+ years' experience of Human Resources (HR), Learning & Development as well as Sales and Marketing in global organizations. She has held various positions within the medtech and the life science industries at companies such as Cochlear Bone Anchored Solutions, Mölnlycke Health Care and Pfizer, and now latest as VP Global HR for Surgical Science. Her vast experience covers functional responsibility for HR as well as line manager positions within sales from the life science industry. Catharina Nordlund will be part of the Executive Management and report to the CEO and President.
Recent Insider Transactions • Nov 18Group Chief Financial Officer recently bought €75k worth of stockOn the 15th of November, Jacob Thordenberg bought around 18k shares on-market at roughly €4.30 per share. This transaction increased Jacob's direct individual holding by 19x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Jacob's only on-market trade for the last 12 months.
お知らせ • Nov 15+ 4 more updatesBICO Group AB (publ) to Report Fiscal Year 2023 Results on Mar 15, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Mar 15, 2024
Reported Earnings • Aug 23Second quarter 2023 earnings released: kr12.73 loss per share (vs kr0.68 profit in 2Q 2022)Second quarter 2023 results: kr12.73 loss per share (down from kr0.68 profit in 2Q 2022). Revenue: kr568.8m (down 3.1% from 2Q 2022). Net loss: kr898.3m (down kr941.9m from profit in 2Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 22+ 1 more updateBICO Group AB (publ) Announces Chief Executive Officer ChangesBICO Group AB (publ) announced that Erik Gatenholm, after initiating discussions with the Board of Directors, has decided to step down as CEO of BICO Group. Maria Forss has been appointed as CEO. Maria Forss will assume office on November 27, 2023, or sooner. Maria Forss (born 1972) has extensive international experience from leading positions in both medtech and pharma companies, such as Vitrolife and AstraZeneca. The last years within Vitrolife Maria Forss has as the Senior Vice President led the Consumables Business Area and before that she was the Vice President of Business Development and Global Marketing. Maria Forss has successfully developed businesses through the whole value chain and in the whole product life cycle as well as acquisitions and integration of companies. In order to enable a seamless transition, Erik Gatenholm will remain in his current position until Maria Forss assumes as new President and CEO. To secure continuity Erik Gatenholm will, as major shareholder, also remain in his role as board member of BICO.
お知らせ • Aug 04Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million.Beos Light Industrial Germany 1 Fund, a fund managed by BEOS AG agreed to acquire property on Wagner-Régeny-Straße 15 from BICO Group AB (publ) (OM:BICO) for €21 million on August 3, 2023. According to customary processes, the transaction needs to seek approval by the city of Berlin and that is expected to take up to 3 months to complete. The transaction is expected to be completed in Q4, 2023. White & Case LLP acted as legal advisor and JLL acted as broker to BICO.
お知らせ • May 10BICO Group AB (publ) Elects Gerry Mackay to Its Board of DirectorsBICO Group AB (publ) at its Annual General Meeting held on 9 May 2023, elected Gerry Mackay to Its Board of Directors.
Reported Earnings • May 08First quarter 2023 earnings released: kr1.67 loss per share (vs kr0.68 loss in 1Q 2022)First quarter 2023 results: kr1.67 loss per share (further deteriorated from kr0.68 loss in 1Q 2022). Revenue: kr537.6m (up 3.6% from 1Q 2022). Net loss: kr117.7m (loss widened 170% from 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
お知らせ • May 05BICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024BICO Group AB (publ) announced that they will report fiscal year 2023 results on Feb 20, 2024
Reported Earnings • Feb 22Full year 2022 earnings released: kr13.00 loss per share (vs kr3.97 loss in FY 2021)Full year 2022 results: kr13.00 loss per share (further deteriorated from kr3.97 loss in FY 2021). Revenue: kr2.53b (up 84% from FY 2021). Net loss: kr832.9m (loss widened 266% from FY 2021). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions • Jan 14Independent Chairman of the Board recently sold €747k worth of stockOn the 10th of January, Carsten Browall sold around 80k shares on-market at roughly €9.33 per share. This transaction amounted to 71% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Carsten has been a net seller over the last 12 months, reducing personal holdings by €654k.
お知らせ • Jan 06BICO Group AB Appoints Marius Balger as Chief Operating Officer, Effective March 1, 2023BICO Group AB announced the appointment of Marius Balger as Chief Operating Officer, as BICO continues to accelerate its growth journey across geographies and business strategies. Mr.Balger will be part of the Executive Management team and report directly to President & CEO Erik Gatenholm. As COO, Mr. Balger will take office 1 March 2023 and lead the strategic development of BICO’s operational efficiency and cost control. Mr. Balger brings nearly 20 years of experience in the global life science industry, most recently serving as Senior Vice President, Commercial Operations at Tecan AG, a public life science company headquartered in Zurich, where he has worked since 2017. Before Tecan AG, Mr. Balger had a long and esteemed career as CEO, successfully growing a global Contract Development and Manufacturing Organization for life science and in-vitro diagnostics laboratory instrumentation. In line with BICO's previously communicated strategy with a focus on cost control, operational efficiency, and decentralized organizational structure the Executive Management of BICO Group will, as of January 5, 2023, consist of the following people: President and CEO Erik Gatenholm; CTO Hector Martinez; CFO Jacob Thordenberg and SVP & General Counsel & HR Lotta Bus. As of 1 March 2023, both COO Marius Balger and Head of Corporate Development & M&A Artur Aira are included in the Executive Management team.
お知らせ • Jan 03BICO Group AB Announces the Appointment of Jacob Thordenberg as Group CFOBICO Group AB announced the appointment of Jacob Thordenberg as Group CFO. Thordenberg will begin his employment in his new position as Group CFO, on January 2, 2023, and will be part of the company's executive management team. Jacob Thordenberg has a Master of Science in Corporate and Financial Management, and has more than ten years' experience from mergers and acquisitions from Deloitte, Telia and BICO Group AB. Most recently he comes from a role as Head of M&A at BICO, where he has been since December 2021. Thordenberg succeeds Mikael Engblom, who has been interim Group CFO since May 2022. Engblom will continue to advise the company on strategic projects.
お知らせ • Nov 22BICO Group AB (publ) to Report Q1, 2023 Results on May 04, 2023BICO Group AB (publ) announced that they will report Q1, 2023 results on May 04, 2023
Buying Opportunity • Nov 16Now 28% undervaluedOver the last 90 days, the stock is up 70%. The fair value is estimated to be €9.27, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 85% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 59% in 2 years. Earnings is forecast to grow by 881% in the next 2 years.
Reported Earnings • Nov 10Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr623.2m (up 79% from 3Q 2021). Net income: kr66.4m (up kr170.6m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • Nov 10BICO Group AB (publ) to Report Q2, 2023 Results on Jul 20, 2023BICO Group AB (publ) announced that they will report Q2, 2023 results on Jul 20, 2023
お知らせ • Oct 29+ 1 more updateBICO Group Announces Appointment of Nomination Committee 2023BICO Group´s major owners have appointed a Nomination Committee. The Annual General Meeting of BICO Group AB will be held on May 9, 2023. In preparation for the 2023 Annual General Meeting the members of the Nomination Committee have been appointed based on the ownership structure as per 30th of September 2022 and consists of: Mats Engström, nominated by Erik Gatenholm. Claes Dinkelspiel, nominated by Héctor Martínez. Malin Björkmo, nominated by Handelsbanken Fonder. Jannis Kitsakis, nominated by Fourth Swedish National Pension Fund. Carsten Browall, Chairman of the Board of BICO Group AB.
Breakeven Date Change • Oct 22Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 112% is required to achieve expected profit on schedule.
Reported Earnings • Aug 24Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr612.4m (up 88% from 2Q 2021). Net income: kr43.6m (up kr93.9m from 2Q 2021). Profit margin: 7.1% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 18%, compared to a 13% growth forecast for the Life Sciences industry in Germany.
Breakeven Date Change • Jul 21Forecast breakeven date moved forward to 2022The 2 analysts covering BICO Group previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr12.0m in 2022. Earnings growth of 105% is required to achieve expected profit on schedule.
Buying Opportunity • Jun 14Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 36%. The fair value is estimated to be €11.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 91% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • May 19First quarter 2022 earnings released: kr0.68 loss per share (vs kr0.90 loss in 1Q 2021)First quarter 2022 results: kr0.68 loss per share (up from kr0.90 loss in 1Q 2021). Revenue: kr537.4m (up 250% from 1Q 2021). Net loss: kr43.6m (loss narrowed 8.2% from 1Q 2021). Over the next year, revenue is forecast to grow 41%, compared to a 13% growth forecast for the industry in Germany.
お知らせ • May 18+ 1 more updateBICO Group AB (publ) to Report Fiscal Year 2023 Results on Feb 22, 2023BICO Group AB (publ) announced that they will report fiscal year 2023 results on Feb 22, 2023
お知らせ • May 12BICO Group Adds Åsa Hillsten as SVP and Head of IRÅsa Hillsten has been appointed SVP and Head of IR at BICO and will be a member of the company's executive management This newly created position constitutes a step in BICO's continued efforts to increase the service level to the market, improve the clarity of its communication and clarify its business model for the investor market. Åsa Hillsten has more than fifteen years of solid experience in international strategic communication and IR issues at the executive management level at growth companies in several sectors. Former positions include Head of IR and communication roles at Catena Media (mid-cap) and Collector Bank (large cap), where she was also Head of PR. Hillsten will assume her position on August 8, 2022, but she will assist the company in an advisory capacity starting in May.
お知らせ • May 08BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million.BICO Group AB (publ) (OM : BICO) acquired Allegro 3D for $11 million on May 6, 2022. As a part of consideration the shareholders of Allegro will receive $5 million as Earnout Payment contingent on Allegro 3D's financial performance in the coming two years. BICO Group AB (publ) (OM : BICO) completed the acquisition of Allegro 3D on May 6, 2022.
お知らせ • May 02BICO (publ) Appoints Mikael Engblom as Interim CFOMikael Engblom will take the position as interim CFO for BICO (publ) from 29 April 2022 until a new permanent CFO is in place. Engblom will be part of Group management during this period. Engblom most recently came from the role of CFO at Vitrolife. Prior to that, he worked as a controller at Vitrolife and Volvo Cars.
Buying Opportunity • Apr 28Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 44%. The fair value is estimated to be €11.99, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 89% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 67% in a year. Earnings is forecast to grow by 83% in the next year.
Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. No highly experienced directors. Independent Director Bengt Sjoholm is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 27+ 1 more updateBICO Group AB (Publ) Announces Board AppointmentsBICO Group AB (publ) at its annual general meeting held on April 26, 2022 elected Rolf Classon and Ulrika Dellby as new members of the Board of Directors.
Recent Insider Transactions • Mar 04Co-Founder recently bought €94k worth of stockOn the 2nd of March, Erik Gatenholm bought around 6k shares on-market at roughly €15.89 per share. In the last 3 months, they made an even bigger purchase worth €1.9m. Despite this recent buy, Erik has been a net seller over the last 12 months, reducing personal holdings by €15m.
Reported Earnings • Feb 24Full year 2021 earnings: EPS in line with analyst expectations despite revenue beatFull year 2021 results: kr3.97 loss per share (down from kr0.82 loss in FY 2020). Revenue: kr1.43b (up 283% from FY 2020). Net loss: kr227.6m (loss widened kr191.5m from FY 2020). Post-clinical trial products Launched (during full year): 3 Revenue exceeded analyst estimates by 2.4%. Over the next year, revenue is forecast to grow 66%, compared to a 25% growth forecast for the pharmaceuticals industry in Germany.
お知らせ • Feb 24BICO Reaches Beneficial and Sustainable Solution with OrganovoBICO have reached a settlement with Organovo in which BICO agreed to resolve all aspects of the disputes between the parties. Organovo and BICO were engaged in several legal disputes regarding Organovo's patents. Under the new agreement, all civil actions regarding potential infringements and IPRs concerning validity of Organovo's patents are dismissed and/or terminated. Both BICO and Organovo have released each other from all previous claims, demands, liabilities and costs in favor of finding a beneficial and sustainable solution created through this patent license agreement. The patent license agreement with Organovo provide BICO with possibilities to access Organovo's bioprinting technologies, which will further empower BICO to continue to advance and expand BICO's product portfolio. BICO offering will become even stronger by accessing these technologies and BICO, through group company CELLINK, will have the freedom to operate globally with the strongest and most extensive bioprinting portfolio on the market. The total annual revenue covered by the license agreement is expected to, as previously communicated via release on January 11, 2022, amount to approximately 1-2% of the Group's estimated revenues in 2022 and therefore is deemed as non-material for the Group.
お知らせ • Feb 03DISPENDIX, A BICO Company, Announces That the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022DISPENDIX, a BICO company, announces that the I.DOT HT Non-contact Dispenser and the L.DROP Liquid Handler will be introduced at SLAS 2022. Driven by several years of growth of the I.DOT non-contact Dispenser, DISPENDIX has invested in strategic R&D and industry partnerships to deliver two disruptive platforms that will come together to provide scientists with more holistic workflow solutions for genomics and drug discovery research. The I.DOT HT builds on the core technology of the I.DOT, expanding the source well layout to a 384 format to support the management of compound libraries at large pharmaceutical and smaller biotechnology companies. The I.DOT HT provides the same degree of precision and process safety that users have come to expect from the DISPENDIX family of products, while expanding the applicability of the I.DOT; now users can seal and store source plates that contain compound libraries for assay development, optimization, and screening. DISPENDIX has also announced the introduction of the L.DROP Liquid Handler with the goal of commoditizing laboratory automation. The L.DROP couples sensor technology and a web-based architecture to provide a more dynamic instrument that is capable of scaling protocols across instruments and even laboratories without tedious optimization. Features like automated deck calibration, web-based protocol fitting, and closed-loop pipetting promise to revolutionize the way that researchers and automation engineers leverage liquid handling technologies. This launch is the latest in DISPENDIX's mission to deliver simple and elegant solutions for the liquid handling industry. These products will be on display and demoed at the upcoming SLAS (Society for Laboratory Automation and Screening) in Boston from February 7-9, 2022 at booth 2727.
お知らせ • Jan 12BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against CellinkDue to recently filed counterclaims in patent lawsuit by Organovo, Inc., (Organovo) to the Federal Court in Delaware, BICO Group AB (BICO) released the following statement to explain the background and context. BICO, CELLINK and all its group companies respect valid intellectual property and believe that Organovo's patent claims at issue are invalid, not infringed, or both. CELLINK filed a complaint for a declaratory judgment in June 2021 to the U.S. District Court in Delaware about non-infringement of certain of Organovo's patents in order to strengthen its market position and freedom to operate. In July, 2021, Organovo, filed a patent infringement action against CELLINK in the U.S. District Court in the Western District of Texas, asserting that a single CELLINK product family infringes four U.S. patents. Organovo'sTexas Court Action was later, in December 2021, transferred to the Delaware Court and both cases will from now on be tried by the Delaware court. The so-called counterclaims filed by Organovo in January 2022 refers to the transferred claims from the Texas Court.
Recent Insider Transactions • Dec 18Co-Founder recently bought €1.9m worth of stockOn the 16th of December, Erik Gatenholm bought around 74k shares on-market at roughly €26.32 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Erik has been a net seller over the last 12 months, reducing personal holdings by €15m.
お知らせ • Dec 17BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc.BICO Group AB (publ) (OM:BICO) agreed to acquire Biosero Llc on December 16, 2021. Approximately 63 percent of the purchase price will be paid in cash, 21 precent by issuance of the Considerations Shares, and approximately 16 percent will be paid through an earnout component (shares and cash) over the coming three years. At closing 1.2 million Consideration shares will be issued to the sellers. Biosero will remain under current entity and management post-transaction. Biosero has an enterprise value of $165 million. BICO’s Board of Directors will resolve to issue the Consideration Shares in accordance with the authorization from the Extraordinary General Meeting held on November 17, 2021. The Acquisition’s completion and the transfer of Biosero’s shares will take place as soon as reasonably possible after signing, provided that all conditions for completion are met. In addition, and as a closing pre-condition, the completion of the Acquisition is dependent on approval by the relevant competition authorities. Biosero will be consolidated in BICO's financial statements and in the financial reporting from Q1, 2022. Foley & Lardner acts as legal advisors to BICO in connection with the Acquisition, PwC advises on financial and tax due diligence.
Reported Earnings • Nov 12Third quarter 2021 earnings releasedThe company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr347.3m (up 457% from 3Q 2020). Net loss: kr104.2m (loss widened kr90.0m from 3Q 2020).
Recent Insider Transactions • Sep 01Insider recently sold €1.1m worth of stockOn the 23rd of August, Jonas Schondube sold around 20k shares on-market at roughly €53.24 per share. In the last 3 months, there was an even bigger sale from another insider worth €17m. Insiders have been net sellers, collectively disposing of €50m more than they bought in the last 12 months.
お知らせ • Aug 28BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million.BICO Group AB (publ) (OM:BICO) acquired all outstanding shares in Advanced BioMatrix, Inc. for $18 million on August 27, 2021. The consideration settled on a cash and debt-free basis of approximately $15 million, provided that the working capital upon completion of the transaction corresponds to the normalized working capital. The sellers may also receive a maximum additional earn out of $3 million in cash based on milestones over a three-year period. Advanced BioMatrix obtained approximately USD 3 million, with an adjusted EBITDA margin of around 50% in their latest fiscal year. Post transaction, Advanced BioMatrix will remain under current legal entity and management as a subsidiary of BICO Group Bioprinting and become part of the Bioprinting business area. Advanced BioMatrix will be integrated in the financial reporting as of August 2021. BICO Group AB (publ) (OM:BICO) completed the acquisition of all outstanding shares in Advanced BioMatrix, Inc. on August 27, 2021.
Recent Insider Transactions • Aug 25CEO & Director recently sold €17m worth of stockOn the 18th of August, Erik Gatenholm sold around 280k shares on-market at roughly €59.24 per share. This was the largest sale by an insider in the last 3 months. This was Erik's only on-market trade for the last 12 months.
Reported Earnings • Aug 21Second quarter 2021 earnings released: kr0.89 loss per share (vs kr0.58 loss in 2Q 2020)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr328.4m (up kr275.8m from 2Q 2020). Net loss: kr50.3m (loss widened 99% from 2Q 2020).
お知らせ • Jul 03CELLINK Receives Patent for Robotic Systems for Personalized and Automated Aesthetic Medical ProceduresCELLINK has been granted a patent for a unique set of robotic systems for transcutaneous delivery of substances, such as cosmetic or surgical fillers, into patients. This is CELLINK’s first granted patent in the field of personalized and automated aesthetic medical procedures - combining the strengths of 3D bioprinting, biomaterials, robotics, automation, and artificial intelligence to optimally administer substances, such as dermal fillers, into subcutaneous regions to improve aesthetical outcomes in patients. This is one technological example of the power of Bioconvergence. This patent protection applies to the Swedish market. The company is also expanding patent protection in the USA and other important markets. The patent protection (SE 543714) from the Swedish Patent and Registration Office shows novelty, inventive step, and industrial applicability. Aesthetic plastic surgery is a field where CELLINK sees great opportunities and potential to disrupt by personalizing, digitizing, and automating the processes. The patented invention covers the use of a person’s 3D face scan as a digital input to compare to the person’s desired bodily features. Based on the results from the artificial intelligence powered algorithm, determine an optimal substance dispensing plan that can be executed autonomously and precisely by a robotic arm in the required facial regions with the adequate type of dermal filler and amounts. The personalized and automated approach may provide a faster and more accurate substance dispensing plan than a human counterpart would be able to do, may reduce treatment times and probability of complications associated with dispensing the substance, while simultaneously achieving superior results compared to the human counterpart.
お知らせ • Jul 01Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc.Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Discover Echo Inc. for $110 million on June 26, 2021. The consideration is on a cash- and debt-free basis, and under the assumption that the working capital at closing equals the normalized working capital. Pursuant to the agreement, Cellink AB (publ) shall pay approximately 11% of consideration through issuance of shares of series B while remaining payable in cash. Discover Echo Inc. will remain under current entity and management post-transaction. Cellink AB (publ) Board of Directors will resolve on an issue in kind of the Consideration Shares in accordance with the authorization from the Annual General Meeting held on April 26, 2021. Post satisfaction of all conditions for the transaction, completion will take place as soon as possible. Foley & Lardner acted as legal advisors to CELLINK in connection with the transaction while Duff & Phelps advises on financial and tax due diligence. Cellink AB (publ) (OM:CLNK B) completed the acquisition of Discover Echo Inc. on June 30, 2021. Total purchase price of $110 million of which approximately $12.5 million was paid in 0.26 million newly issued shares of series B in CELLINK and the reminder in cash.
お知らせ • Jun 01Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million.Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for approximately €50 million on May 19, 2021. The consideration is on cash- and debt-free basis. Consideration consists of approximately €34 million as fixed purchase price and approximately €16 million in earn-outs. Approximately 35% of the fixed purchase price of €34 million will be paid in newly issued shares of series B in CELLINK and the remaining portion will be paid cash. The earn-out is paid based on target fulfillment of financial targets for the fiscal years 2021–2023. Hans-Jörg Ziegenhain, Elisabeth Kreuzer, Markus Ernst, Dirk Uwer, Hendrik Bockenheimer, Jakub Lorys, Susanne Koch and Patrick Wilkening of Hengeler Mueller Partnerschaft von Rechtsanwälten mbB acted as legal advisors, Duff & Phelps GmbH acted as financial and tax due diligence provider and Zacco Gmbh acted as intellectual property due diligence provider to Cellink. Cellink AB (publ) (OM:CLNK B) completed the acquisition of Nanoscribe GmbH for approximately €37 million on May 31, 2021. The purchase price for all shares amounted to approximately €36.9 million based on net cash/debt and of which approximately €12.2 million was paid in 301,332 newly issued shares of series B in CELLINK and the reminder in cash.
お知らせ • May 21Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million.Cellink AB (publ) (OM:CLNK B) entered into an agreement to acquire Nanoscribe GmbH for €34 million on May 19, 2021. Consideration consists of approximately €16 million in earn-outs. The earn-out is paid based on target fulfillment of financial targets for the fiscal years 2021–2023. Approximately thirty-five percent of the fixed purchase price of €34 million will be paid in newly issued shares of series B in CELLINK (the “Consideration Shares”) and the remaining part which consists of an earn-out will be paid cash. Hengeler Mueller Partnerschaft von Rechtsanwälten mbB acted as legal advisor, Duff & Phelps GmbH acted as financial and tax due diligence provider and Zacco Gmbh acted as intellectual property due diligence provider to Cellink.